LCM
SLN

Lynx1 Capital Management’s Silence Therapeutics SLN Stock Holding History

Lynx1 Capital Management’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-526,642
Closed -$11.4M – 20
2024
Q1 		$11.4M Buy
526,642
+290,855
+123% +$6.32M 2.93% 8
2023
Q4 		$4.1M Hold
235,787
– – 1.61% 10
2023
Q3 		$2.32M Buy
+235,787
New +$1.74M 1.53% 11

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Lynx1 Capital Management's SLN Position: Q2 2024 in Review

Lynx1 Capital Management sold out of Silence Therapeutics (SLN) in Q2 2024, closing a stake of 526,642 shares — an estimated $11.4M sold.

Lynx1 Capital Management first reported a position in SLN in Q3 2023 and held it in 3 quarters. The position peaked at $11.4M in Q1 2024. 71 funds tracked by Wall St. Rank hold SLN as of Q2 2024.

  • Lynx1 Capital Management reported no remaining Silence Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Lynx1 Capital Management sold 526,642 Silence Therapeutics shares in Q2 2024, an estimated $11.4M.
  • Lynx1 Capital Management first reported a position in Silence Therapeutics in Q3 2023 and held it in 3 quarters.
  • Lynx1 Capital Management's Silence Therapeutics position peaked at $11.4M in Q1 2024.
  • 71 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2024.

Based on Lynx1 Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.